Mary Kay Inc. Names Wendy Wang President for the Asia Pacific Region
11.3.2021 05:11:00 EET | Business Wire | Press release
Global beauty brand Mary Kay Inc., a leading corporate advocate of women’s entrepreneurship and empowerment, with its global headquarters in Addison, Texas, U.S.A, recently announced the appointment of Wendy Wang as President of its Asia Pacific Region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210310005138/en/
Wendy Wang, President of Mary Kay’s Asia Pacific Region (Photo: Mary Kay Inc.)
In her new role, Wang will provide strategic vision and leadership while working to create growth for the Company in the Asia Pacific region and beyond. Wang joined Mary Kay’s Corporate Legal Department in 2002 as Counsel for the Asia Pacific region. Shortly thereafter, she began a multi-year assignment in China. Upon her return to the global corporate headquarters in 2012, she was promoted to the position of Vice President and Associate General Counsel where she was responsible for legal work and compliance in all four regions. In 2019, Wang returned to China for a new assignment and was promoted to the position of Chief Commercial Officer for the Asia Pacific Region in 2020. In this role, she developed and drove the implementation of commercial strategies, and lead the Asia Pacific regional team in support of sales, marketing, business technology and operations, preparing her to take on the challenge of the Region President responsibilities.
“We want to congratulate Wendy as she transitions into her new role as President of Mary Kay Asia Pacific,” said David Holl, Mary Kay Chairman and Chief Executive Officer. “Wendy is passionate for the Mary Kay independent sales force and is a proven leader within Mary Kay. During her tenure, she has tirelessly built a strong and talented legal team that created a culture of compliance and compassion for China and the entire Asia Pacific Region. We are thrilled to welcome her as a member of the executive committee as we build on our efforts to enrich women’s lives around the globe.”
A graduate of The University of Texas at Austin, Wang earned her law degree as well as an undergraduate degree in Economics. She has received numerous honors and accolades including her recognition in 2017 by D CEO magazine as ‘Outstanding Deputy General Counsel/Associate General’ and the Greater Dallas Asian American Chamber of Commerce ‘Corporate Executive Diversity’ award.
“I am committed to empowering women and their families in the Asia Pacific region,” says Wang. “Supporting Mary Kay’s independent sales force is my greatest honor and always brings me hope, love and confidence in our future. We are a people business with a mission to enrich women’s lives and a vision to empower the Independent Beauty Consultant. My team and I are committed to delivering the very best business opportunity, building upon the values Mary Kay upholds as cornerstones of our corporate culture and mission.”
The promotion of Wang is the latest in Mary Kay Inc.’s decades-long commitment to empowering women to serve in leadership positions around the globe. Mary Kay is a company built by women for women, and that core value is reflected in Mary Kay’s global workforce gender diversity data (as of March 2021):
- 61% of Mary Kay’s global workforce is female
- 59% of Directors and above are female
- 54% of Global Vice Presidents and above are female
- Over 50% of Mary Kay’s global executive team is female
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company nearly 60 years ago with three goals: develop a rewarding opportunity for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay Inc. is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances which are sold exclusively by Mary Kay independent beauty consultants.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005138/en/
Contact information
Mary Kay Inc. Corporate Communications
Marykay.com/newsroom
(+1) 972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom